Trius Therapeutics to Present Data From Tedizolid Clinical Studies at IDWeek Conference

SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its lead antibiotic drug candidate, tedizolid phosphate, will appear in poster presentations at the inaugural IDWeek conference, a joint meeting of the Infectious Disease Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Disease Society, in San Diego from October 17th to 21st. Two tedizolid-related posters have been accepted for presentation, including clinical and safety results.

Back to news